January 30: The Week in Cancer News
Older adults with metastatic cancer are spending more time at medical appointments, and a biomarker test improves the odds of detecting pancreatic cancer.
Progress Against Cancer
Older adults with metastatic cancer are spending more time at medical appointments, and a biomarker test improves the odds of detecting pancreatic cancer.
The four-biomarker blood panel enhanced the detection of pancreatic cancer compared to standard testing. The pancreas aids with digestion and produces hormones, such as insulin and glucagon, that help regulate blood sugar levels. When...
What does a naked mole rat, a nuclear exporter that “moonlights” as a chromatin regulator, and the combined power of tissue and liquid biopsy all have in common? They are all at the heart...
The FDA has approved daratumumab and hyaluronidase-fihj in combination with other therapies as first-line treatment for certain patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro)...
A vaccine helps reduce recurrences in melanoma, and a blood test may predict which small cell lung cancer patients will respond to immunotherapy.
Cancer Today's winter 2025-2026 issue covers delaying stem cell transplants in multiple myeloma, new treatments for brain metastases, and more.
What are fusion proteins? Learn more about how improperly combined genes and their protein products can lead to cancer.
Government cuts to research limit options for children with rare cancers, and a study links exercise with lower fatigue for people with colorectal cancer.
At an AACR special conference on early-onset cancers, researchers discussed microplastics, the global rise of these cancers, and more.
ctDNA status may also inform treatment plan. Breast cancer is the most common form of non-skin cancer in the United States, and human epidermal growth factor receptor 2-positive breast cancer, or HER2-positive breast cancer,...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More